Letters to the Editor
Wegener's Granulomatosis Presenting as Rheumatoid Arthritis From Professor I Friedmann Professor Emeritus ofPathology, Northwick Park Hospital and Clinical Research Centre, Harrow, Middlesex, HA] 3UJ Dear Sirs, I have read with great interest the paper on 'Wegener's Granulomatosis Presenting as Rheumatoid Arthritis' by M H Pritchard and P J Gow (July Proceedings, p 501) illustrating the diagnostic difficulties and the variable and subtle natural history of the disease.
The systemic lesions of Wegener's granulomatosis are usually preceded by the nasal lesions; hence Wegener's original term 'rhinogenic granulomatosis'. It is, therefore, interesting to note that in the two cases here described the nasal lesions seem to have developed subsequently in the course of the presenting rheumatoid arthritis; in fact, providing the relevant diagnostic clues. Nasal lesions can remain asymptomatic, but it may be suggested that an earlier examination of the nasal mucosa might have revealed some early pathological changes, such as fibrinous vasculosis and occasional giant cells in some nonspecific histiocyte granulation tissue.
In this context I believe that the concept of the localized form of Wegener's granulomatosis as suggested by Fienberg (1953, American Journal of Clinical Pathology 23, 413; 1974, Lancet i, 574) and by Carrington & Liebow (1966, American Journal of Medicine 41, 497) has to be strongly supported although frowned upon by Wegener himself (1968, Morgagni 1, 5) and by the authors.
The earliest diagnosis of Wegener's granuloma, in the apparent absence of systemic lesions of any kind, has acquired an added urgency since the introduction of potent cytotoxic drugs capable of arresting the disease. Spontaneous remissions also occur. Atypical cases should more often be reported both as a salutary reminder of the diagnostic difficulties and assisting in the elucidation of the etiological factors. It has been suggested that the disease is an immunologically mediated disorder and that also applies to rheumatoid arthritis.
Part of the existing confusion derives from the fact that some authors hold to the original definitions whereas others offer modifications (Fienberg, 1974; Michaels, 1976, in: Scientific Founda-tions of Otolaryngology, Ed. Hinchcliffe & Harrison. Heinemann, London, p 671; &c.). It is not easy to find pathologists or clinicians who will agree completely about all aspects of classification and the literature is replete with modifying diagnostic terms.
Since the localized form of Wegener's granulomatosis bears some topographic and clinical resemblance to the idiopathic midline granuloma or Stewart's type nonhealing granuloma of the nose (Fauci & Wolff, 1976, Annals of Internal Medicine 84, 140; Friedmann, 1964, Proceedings 57, 289; 1971, Journal of Laryngology 85, 631; Friedmann & Osborn, 1976 Radiology (August Proceedings, p 543) to discuss osteosarcoma has one important inference: apart from the intrinsic quality of the papers, which clearly set out the present state of knowledge of this difficult and often harrowing disease, the very fact that osteosarcoma is discussed at a joint meeting emphasizes the need to manage patients with suspected malignant disease of bone at clinics in which all appropriate disciplines are represented.
Our experience over the years in a Bone Tumour Panel has shown the great advantages which accrue to the patient and those responsible for his treatment when each case is formally discussed by a group of specialists with varying experience.
The Proceedings reached me simultaneously with the Newsletter from the MRC Working Party on Osteosarcoma. It is becoming increasingly clear that, if we are to make a significant breakthrough in the treatment of osteosarcoma, not only should these' patients be diagnosed and managed by an interdisciplinary group, but every effort should be made to treat all cases within the general orbit of this important national trial. (July, p 467) raises certain interesting points. While it remains unproven from this paper that patients with circulating malignant cells have a better prognosis than those patients in whom they are not demonstrated (the groups are unmatched, with significantly more A and B cases in the groups with circulating malignant cells) the thesis is attractive. If the number of circulating malignant cells is raised by giving fibrinolytic agents such as urokinase, would not the use of other methods to prevent thrombosis and platelet adhesion give similar results? With the great interest over the last few years in the prophylactic treatment to prevent deep vein thrombosis after many surgical procedures by the use of low-dose heparin or dextran infusion it would be pertinent to ask whether any of your readers have found a similar beneficial effect from these drugs, on the prognosis of both colorectal and other carcinomas.
It has also been suggested that protease and collagenase inhibitors such as aprotinin have a similar beneficial effect on reducing metastases in experimental animals. Yours faithfully P R HAWLEY 9 August 1976 A copy of Mr Hawley's letter was sent to Mr White and his co-authors and their reply appears below:
Dear Sir, We fully accept the statistical limitations in analysing our data and deliberately avoided suggesting a high degree of significance in such a small group with differing numbers of unmatched Dukes A, B and C cases -merely stating P values for the two main groups.
However, among the C cases (the most numerous group) it is worth noting that there was a 40 % survival when circulating malignant cells were present but only an 11% survival when malignant cells were not found. Our data were actually analysed as regards the overall survival at ten years in relation to the various states and as regards A, B and C classification within each group. The numbers involved are on the small side but when assessing the distribution of survival between categories A, B and C at ten years, there is a significant difference between dead and alive patients (P=0.5 %), with 'dead' showing excess C and shortfall in A and 'alive' the reverse.
There has been a great deal of experimental work with animal tumours suggesting that in certain systems anticoagulants and other agents such as ancrod (purified Malayan pit viper venom) can reduce metastases. The first clinical survey of patients on long-term anticoagulants which suggested a benefit was that by Michaels (1964, Lancet ii, 832 Stage II carcinoma of the cervix gave rise to some hope that we might receive guidance on the management of this problem. In so far as treatment is concerned the papers as reported in the Proceedings (September, pp 673-686) are somewhat disappointing. Dr Cole advocates radium therapy alone for 'early' cases, Mr Feroze radiotherapy followed by surgery and Dr Baker varies her treatment with the histology and with the
